Modern Radiotherapy for a Medieval Malady: An Analysis of Treatment Toxicities for Locally Advanced Head and Neck Cancers

IF 0.4 Q4 ONCOLOGY
Fathima Almas, Anshul Singh, K. Sharan, S. Lewis, S. A. Reddy, Umesh Velu, P. Augustine
{"title":"Modern Radiotherapy for a Medieval Malady: An Analysis of Treatment Toxicities for Locally Advanced Head and Neck Cancers","authors":"Fathima Almas, Anshul Singh, K. Sharan, S. Lewis, S. A. Reddy, Umesh Velu, P. Augustine","doi":"10.30476/MEJC.2021.84516.1235","DOIUrl":null,"url":null,"abstract":"Background: Concurrent chemo-radiation has proven to be beneficial in a majority of patients with locally advanced head and neck cancers. Despite modern techniques of radiation delivery, the trade-off is acute and entails late toxicities for a considerable number of patients. Very few studies have reported the outcomes of these patients. We aimed to prospectively assess and report the toxicities of patients undergoing definitive chemo-radiation by the Volumetric Modulated Arc Therapy (VMAT) for the treatment of advanced laryngeal and hypopharyngeal cancer. \nMethod: This prospective observational study was conducted in a single tertiary care center over a period of two years. We recorded acute and late toxicities during and after the treatment of patients with locally advanced laryngeal and hypopharyngeal cancer treated with definitive chemo-radiotherapy using VMAT. Chi square test and Fisher’s exact test were used for comparing the significance of outcome parameters with different variables. \nResults: 28 patients who met the inclusion criteria were taken up for analysis. The median age was 59 years. The median treatment time was 48 days. The mean dose to parotid, superior, and mid constrictors was 32, 45, and 64 Grays (Gy). At completion, 7% of the patients had grade 3 or more dermatitis, 4% had grade 3 or higher mucositis, and no patient had grade 3 or higher xerostomia. Five patients treated for hypopharynx cancer developed strictures. \nConclusion: Our results showed that concurrent chemo-radiotherapy using VMAT is a promising method of treatment for advanced laryngeal and hypopharyngeal squamous cell cancer with an acceptable toxicity profile.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2021.84516.1235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Concurrent chemo-radiation has proven to be beneficial in a majority of patients with locally advanced head and neck cancers. Despite modern techniques of radiation delivery, the trade-off is acute and entails late toxicities for a considerable number of patients. Very few studies have reported the outcomes of these patients. We aimed to prospectively assess and report the toxicities of patients undergoing definitive chemo-radiation by the Volumetric Modulated Arc Therapy (VMAT) for the treatment of advanced laryngeal and hypopharyngeal cancer. Method: This prospective observational study was conducted in a single tertiary care center over a period of two years. We recorded acute and late toxicities during and after the treatment of patients with locally advanced laryngeal and hypopharyngeal cancer treated with definitive chemo-radiotherapy using VMAT. Chi square test and Fisher’s exact test were used for comparing the significance of outcome parameters with different variables. Results: 28 patients who met the inclusion criteria were taken up for analysis. The median age was 59 years. The median treatment time was 48 days. The mean dose to parotid, superior, and mid constrictors was 32, 45, and 64 Grays (Gy). At completion, 7% of the patients had grade 3 or more dermatitis, 4% had grade 3 or higher mucositis, and no patient had grade 3 or higher xerostomia. Five patients treated for hypopharynx cancer developed strictures. Conclusion: Our results showed that concurrent chemo-radiotherapy using VMAT is a promising method of treatment for advanced laryngeal and hypopharyngeal squamous cell cancer with an acceptable toxicity profile.
中世纪疾病的现代放射治疗:局部晚期头颈癌治疗毒性分析
背景:同时化疗放疗已被证明对大多数局部晚期头颈癌患者有益。尽管有现代的放射治疗技术,但这种权衡是急性的,对相当多的患者来说会产生晚期毒性。很少有研究报告这些患者的结果。我们的目的是前瞻性地评估和报告接受容量调制电弧疗法(VMAT)治疗晚期癌症的最终化疗放疗的患者的毒性。方法:这项前瞻性观察性研究在一个三级护理中心进行,为期两年。我们记录了局部晚期喉部和下咽癌症患者在接受VMAT明确化疗期间和治疗后的急性和晚期毒性。卡方检验和Fisher精确检验用于比较不同变量的结果参数的显著性。结果:28名符合纳入标准的患者被纳入分析。中位年龄为59岁。中位治疗时间为48天。腮腺、上缩肌和中缩肌的平均剂量分别为32、45和64格雷(Gy)。完成时,7%的患者患有3级或以上皮炎,4%的患者患有三级或以上粘膜炎,没有患者患有三度或以上口干症。5名接受下咽癌症治疗的患者出现狭窄。结论:VMAT联合化疗是治疗晚期喉下咽鳞状细胞癌症的一种很有前途的方法,具有可接受的毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信